Buprenorphine/naloxone sublingual tablet (Zubsolv®): a guide to its use in the maintenance treatment of opioid dependence in the USA
- 153 Downloads
Zubsolv® is a new sublingual formulation of buprenorphine/naloxone that is indicated for the maintenance treatment of opioid dependence in the USA. The effectiveness and tolerability of buprenorphine/naloxone in this indication is well established. Relative to other sublingual formulations of buprenorphine/naloxone, Zubsolv® dissolves more rapidly, has greater bioavailability, tastes better, and may be preferred by many patients.
KeywordsNaloxone Buprenorphine Atazanavir Opioid Dependence Opioid Withdrawal
The manuscript was reviewed by: S. Helm, Pacific Coast Pain Management Center, Laguna Hills, CA, USA; M. Hillhouse, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA, C.M. Renzelli, Gateway Rehabilitation Center, Moon Township, PA, USA.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 1.Colson J, Helm S, Silverman SM. Office-based opioid dependence treatment. Pain Physician. 2012;15(3 Suppl):ES231–6.Google Scholar
- 4.Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1 Suppl B):S14–21.Google Scholar
- 6.Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.Google Scholar
- 7.Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008(2):CD002207.Google Scholar
- 12.Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. J Psychoactive Drugs. 2004;Suppl. 2:119–28.Google Scholar
- 15.Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006;43(Suppl 4):S173–7.Google Scholar
- 16.Naloxone hydrochloride injection: US prescribing information. Lake Forest (IL): Hospira, Inc. 2007.Google Scholar
- 17.Zubsolv® (buprenorphine and naloxone sublingual tablets) for sublingual administration (CIII): US prescribing information. New York: Orexo US, Inc. 2013.Google Scholar
- 19.Jönsson M, Fischer A, Tiberg C, et al. A novel buprenorphine/naloxone tablet formulation for the treatment of opioid dependence [poster]. In: 44th Annual Medical-Scientific Conference of the American Society of Addiction Medicine; 25–28 Apr 2013; Chicago.Google Scholar
- 23.Orexo. Orexo takes large step forward on the road to improve treatment for people dependent on opioid pain killers [media release]. 2012 Jul 2 [online]. Available from: http://www.orexo.com/en/Investor-Relations/Press-releases/?guid=680249.
- 25.Kamien JB, Branstetter SA, Amass LA. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl. 2008;10(4):5–18.Google Scholar